Vitreous pharmacokinetics and retinal safety of intravitreal preserved versus non-preserved triamcinolone acetonide in rabbit eyes

Current Eye Research

Volumn 37, Issue 1, 2012, Pages 55-61

  Oliveira, Rafael C ^a,c   Messias, André ^a   Siqueira, Rubens C ^a   Bonini Filho, Marco A ^a   Haddad, Antnio ^a   Damico, Francisco M ^a   Maia Filho, Alfredo ^b   Crispim, Pedro Tb ^c   Saliba, Juliana B ^d   Ribeiro, Jefferson A S ^a   Scott, Ingrid U ^e   Cunha Jr, Armando S ^d   Jorge, Rodrigo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Rio Preto Medical College   (Brazil)

^c Federal University of Rondnia   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Preservative benzyl alcohol; Retina; Triamcinolone; Vitreous pharmacokinetics

Indexed keywords

BENZYL ALCOHOL; TRIAMCINOLONE ACETONIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTRORETINOGRAM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; IN VIVO STUDY; MALE; MICROSCOPY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; RETINA; TOXICITY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; RABBITS; RETINA; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 83655191305     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.593722     Document Type: Article

References (22)

1. Peyman GA, Ganiban GJ. Delivery systems for intraocular routes. Adv Drug Deliv Rev. 1995;16:107-123.
2. Karla PK, Earla R, Boddu SH, Johnston TP, Pal D, Mitra A. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res. 2009;34:1-9.
3. Fialho SL, Rgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, Maia-Filho A, Silva-Cunha A. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res. 2006;31:525-534 (Pubitemid 43884599)
4. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845-3849. (Pubitemid 44264695)
5. Lee H, Shah GK. Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina. 2005;25:551-555. (Pubitemid 41077255)
6. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA. Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg. 2003;29:27-33. (Pubitemid 36152276)
7. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study. Ophthalmology. 2001;108:765-772. (Pubitemid 32238474)
8. Challa JK, Gillies MC, Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281. (Pubitemid 28529891)
9. Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol. 2000;84:1064-1067.
10. Sutter FK, Gillies MC. Pseudo-endophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol. 2003;87:972-974 (Pubitemid 36936293)
11. Moshfeghi AA, Scott IU, Flynn HW, Puliafito CA. Pseudohypopion after triamcinolone acetonide injection for cystoyd macular edema. Am J Ophthalmol. 2004;138:489-492. (Pubitemid 39208586)
12. Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol. 1986;101:190-195. (Pubitemid 16136575)
13. Naka KI, Rushton WA. S-potentials from luminosity units in the retina of fish (Cyprinidae). J Physiol. 1966;185: 587-599.
14. Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lke M, Spitzer MS, Heide PE, Bartz-Schmidt KU. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol. 2007;245:689-696. (Pubitemid 46951235)
15. Kim H, Csaky KG, Gravlin L, Yuan P, Lutz RJ, Bungay PM, Tansey G, DE Monasterio F, Potti GK, Grimes G, Robinson MR. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina. 2006;26:523-530. (Pubitemid 44620393)
16. Oishi M, Maeda S, Hashida N, Ohguro N, Tano Y, Kurokawa N. Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. Jpn J Ophthalmol. 2008;52:489-492.
17. Moshfeghi AA, Nugent AK, Nomoto H, Sanislo SR, Kitchens JW, Moshfeghi DM. Triamcinolone acetonide preparations: Impact of crystal size on in vitro behavior. Retina. 2009;29:689-698.
18. Missel PJ, Horner M, Muralikrishnan R. Simulating dissolution of intravitreal triamcinolone acetonide suspensions in an anatomically accurate rabbit eye model. Pharm Res. 2010;27:1530-1546.
19. Ober MD, Barile GR, Tari SR, Tosi GM, Schiff WM, Chang S. Measurement of the actual dose of triamcinolone acetonide delivered by common techniques of intravitreal injection. Am J Ophthalmol. 2006;142:597-600.
20. Scholes GN, O'Brien WJ, Abrams GW, Kubicek MF. Clearance of triamcinolone from vitreous. Arch Ophthalmol. 1985;103:1567-1569. (Pubitemid 15240750)
21. Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch Clin Exp Ophthalmol. 2006;244:1152-1159. (Pubitemid 44269594)
22. Yu SY, D'Amico FM, Viola F, D'Amico DJ, Young FH. Retinal toxicity of intravitreal triamcinolone acetonide: A morphological study. Retina. 2006;5: 531-536. (Pubitemid 44620394)